Key result
Metabolic syndrome in CKD is linked to ~17% higher arterial stiffness.
Why the study?
Insulin resistance and the metabolic syndrome may contribute to cardiovascular risk in chronic kidney disease, but their association with vascular function in CKD is not well defined.
Are insulin resistance and metabolic syndrome associated with increased arterial stiffness and endothelial dysfunction in patients with stage 3-4 chronic kidney disease?
Cross-Sectional (n=71)
Are insulin resistance and metabolic syndrome associated with increased arterial stiffness and endothelial dysfunction in patients with stage 3-4 chronic kidney disease?
Absolute Event Rate: 9.5% vs 8.1%
p-value: p=0.03
Insulin resistance and metabolic syndrome are independently associated with increased arterial stiffness in patients with stage 3-4 chronic kidney disease, highlighting a potential mechanism for increased cardiovascular risk in this population.
Supports MetS as stiffness contributor in CKD; hypothesis-generating, needs prospective trials before practice change.
BACKGROUND: Insulin resistance (IR) and the metabolic syndrome (MetS) may contribute to cardiovascular risk in chronic kidney disease (CKD). We examine the association between IR and vascular function in CKD. Furthermore, we define the prevalence of MetS and examine the association between defining MetS and vascular function. METHODS: This cross-sectional study of 71 stage 3-4 CKD subjects assessed arterial stiffness (pulse wave velocity (PWV) and endothelial dysfunction (ED). IR was assessed using Homeostasis Model Assessment-IR (HOMA-IR). MetS was defined by the unified International Diabetes Federation and American Heart Association/National Heart Lung and Blood Institute criteria. RESULTS: CKD subjects with HOMA-IR score above the median had significantly higher body mass index and waist circumference. They also had higher PWV, higher triglycerides with lower high-density lipoprotein concentration (P < 0.05). Age, systolic blood pressure, and HOMA-IR were independently associated with PWV, even after exclusion of diabetic subjects (n = 16) (P ≤ 0.05). MetS was more prevalent in CKD (78.9%) than controls (2.5%). MetS in CKD was associated with increased PWV (MetS(+) geometric mean = 9.5 m/s, 95% confidence interval (95% CI) = 8.9-10.2 m/s; vs. MetS(-) 8.1 m/s, 95% CI = 7.1-9.3 m/s; P = 0.03) but not ED. In a multiple logistic regression analysis, PWV higher than the median was independently associated with dysglycemia. CONCLUSIONS: IR is independently associated with arterial stiffness, even in nondiabetic CKD. MetS is common and identified a subgroup of CKD patients with increased arterial stiffness, which is associated with dysglycemia.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2013) conducted a cross-sectional in chronic kidney disease (n=71). Metabolic syndrome vs. Without metabolic syndrome was evaluated on Pulse wave velocity (PWV) (p=0.03). Metabolic syndrome in patients with chronic kidney disease was associated with increased arterial stiffness (pulse wave velocity 9.5 m/s vs 8.1 m/s; P=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: